Table 1.

Experimental groups, treatments at different days post PEDV vaccination (dpv), average daily gain (ADG) in grams from dpv 0 to 42 (corresponds to day post challenge 14), length and area under the curve (AUC) of PEDV RNA shedding in feces

Group designation	Number of pigs	Exposure or vaccination					Challenge	ADGd	Viral shedding in fecesd
		Type	Adjuvant	Genogroup	Route	Timing	dpv 28	dpv 0–42	Length (days)	AUC
EXP-IM-1b	7	Experimental live virus	Adjuplex™	G1b	Intramuscularly	dpv 0	PEDV G2b	412.8 ± 29.8A	10.7 ± 1.5A,e	236.6A
EXP-ORAL-1b	8	Experimental live virus	None	G1b	Orally	dpv 0	PEDV G2b	385.2 ± 27.0A	5.8 ± 0.3A,B	141.9A
VAC-IM-2b	8	Commercial inactivatedc	Amphigen®	G2b	Intramuscularly	dpv 0 and 14	PEDV G2b	402.8 ± 26.1A	2.5 ± 1.6B,C	43.9B
POS-CONTROLa	8	Saline	None	NA	Intramuscularly	dpv 0	PEDV G2b	379.8 ± 19.5A	7.5 ± 1.3A	169.0A
NEG-CONTROLb	8	Saline	None	NA	Orally	dpv 0	Saline	460.0 ± 22.1A	0.0 ± 0.0C	0.0B

^aThe POS-CONTROL group was sham-vaccinated intramuscularly and inoculated with PEDV G2b and served as an unvaccinated, PEDV challenged group.

^bThe NEG-CONTROL group was sham-vaccinated orally with saline and sham-inoculated with saline and served as unvaccinated and unchallenged control group.

^cPorcine Epidemic Diarrhea Vaccine; Zoetis.

^dData presented as group mean ± SEM.

^eDifferent superscripts^(A,B,C) within a column indicate significant (P < 0.05) different group means.